Organized by the NACP Nuclear Medicine Committee
Date and time: 12/5/2025 14:00 CEST- (UTC+2)
Registration link

Program

Introduction, Dr. Antti Pekkarinen

Overview of the re-established nuclear medicine committee.

Tumor dosimetry for mCRPC patients receiving PSMA-targeted radiopharmaceutical therapy
challenges and opportunities, Dr. Julia Brosch-Lenz

The talk will introduce the basics of the dosimetry workflow and the different methods for calculation of absorbed dose. The challenges for tumor dosimetry calculation will be highlighted and discussed as well as outlining the opportunities of routine image-based dosimetry in patient management and towards outcome improvement.

Kidney Dosimetry Protocol Development, Assoc. Prof. Anne Larsson Stromvall

In this talk the Lut-AEAproject (A multicenter study comparing 177Lu-PSMA-I&T versus Apalutamide/Enzalutamide/Abiraterone, in metastatic hormone sensitive prostate cancer) will be presented. The ongoing work of developing a single timepoint dosimetry protocol for the kidney will also be discussed.

Lu-PSMA-Dosimetry in Glioma Patients, Dr. Anna Maria Karlberg

Preliminary results from the GLITHER-study will be presented, with focus on challenges to estimate absorbed doses for heterogeneous tumors and small organs at risk.